Search results

23 results for Ranibizumab

Sorted by Relevance . Sort by Date

  1. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia

  2. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)

  3. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

  4. Eye conditions

    Everything NICE has said on eye conditions in an interactive flowchart

  5. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration

  6. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy

  7. Past appeals and decisions

    degeneration (age-related) - ranibizumab and pegaptanib 30 June 2008 TA237 Macular oedema (diabetic) - ranibizumab: appeal...

  8. Age-related macular degeneration

    Everything NICE has said on age-related macular degeneration in an interactive flowchart